Sign in

CVSI on OTC

CV Sciences, Inc.

American pharmaceutical preparations company based in Las Vegas2

In its 2026 annual report the company says: “CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods. Our hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business to business-to-consumer.”5 Its shares trade on OTC under the symbol CVSI.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Pyxis Oncology, Inc., Arbutus Biopharma or Opus Genetics, Inc., or pick any stock.

  • TickerCVSI on OTC2
  • IndustryPharmaceutical Preparations2
  • HeadquartersLas Vegas, United States2
  • Incorporated inDE3
  • Business address9530 Padgett Street, Suite 107, San Diego, Ca 921263
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300CTTCLKOE31VK582
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 53741442

See how the biggest companies compare on our leaderboards

CV Sciences, Inc. (“CV Sciences,” the “Company,” “we,” “our” or “us”) is a consumer wellness company specializing in nutraceuticals and plant-based foods. Our hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business (“B2B”) to business-to-consumer (“B2C”).5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

49.0%Gross margin6
-3.4%Operating margin6
-6.9%Net margin6
-12.2%Revenue growth, 20256
-65.3%Return on equity6
0.26×Debt to equity6
-$516.0KFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue48¢$7.0M
  • Research and development1¢$122.0K
  • Selling, general and admin52¢$7.6M
  • Income tax0¢$9.0K

Out of $13.8M in revenue.6 The company lost money this year.

Financial statements

Revenue78910116$13.8M in 2025−74% since 2019
0$20.0M$40.0M$60.0M2019: $53.7M$53.7M20192020: $24.4M$24.4M2020−55%2021: $20.0M$20.0M2021−18%2022: $16.2M$16.2M2022−19%2023: $16.0M$16.0M2023−1%2024: $15.7M$15.7M2024−2%2025: $13.8M$13.8M2025−12%
Gross profit78910116$6.8M in 2025−81% since 2019
0$10.0M$20.0M$30.0M$40.0M2019: $35.1M$35.1M20192020: $11.0M$11.0M2020−69%2021: $8.6M$8.6M2021−22%2022: $5.5M$5.5M2022−36%2023: $7.1M$7.1M2023+28%2024: $7.2M$7.2M2024+1%2025: $6.8M$6.8M2025−6%
Operating income78910116-$470.0K in 2025−97% since 2019
-$30.0M-$20.0M-$10.0M0$10.0M2019: -$17.2M-$17.2M20192020: -$22.6M-$22.6M2020+31%2021: -$18.4M-$18.4M2021−18%2022: -$6.8M-$6.8M2022−63%2023: $3.4M$3.4M20232024: -$2.2M-$2.2M20242025: -$470.0K-$470.0K2025−79%
Net income78910116-$958.0K in 2025−94% since 2019
-$30.0M-$20.0M-$10.0M0$10.0M2019: -$16.6M-$16.6M20192020: -$22.3M-$22.3M2020+34%2021: -$15.6M-$15.6M2021−30%2022: -$8.2M-$8.2M2022−47%2023: $3.1M$3.1M20232024: -$2.4M-$2.4M20242025: -$958.0K-$958.0K2025−60%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Product sales, net$13.8M$15.7M
Cost of goods sold$7.0M$8.5M
Gross profit$6.8M$7.2M
Research and development$122.0K$118.0K
Selling, general and administrative$7.6M$9.2M
Benefit from reversal of accrued payroll taxes (Note 12)-$522.0K$0
Total operating expenses$7.2M$9.4M
Operating loss-$470.0K-$2.2M
Gain on extinguishment of debt-$38.0K$0
Interest expense, net$517.0K$212.0K
Loss before income taxes-$949.0K-$2.4M
Income tax expense (benefit)$9.0K-$8.0K
Net loss-$958.0K-$2.4M
Weighted average common shares outstanding, basic (in shares)184.3M shares175.6M shares
Weighted average common shares outstanding, diluted (in shares)184.3M shares175.6M shares
Net loss per common share, basic (in USD per share)-$0.01-$0.01
Net loss per common share, basic diluted (in USD per share)-$0.01-$0.01

Compare CV Sciences, Inc. with another company

Corporate structure

CV Sciences, Inc. sits at the top of its group. 4 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CV Sciences, Inc.

  • Charlie E. Cheever Iii. Filed SCHEDULE 13G on CV Sciences, Inc., latest Sep 9, 2026
  • CV Sciences, Inc. Las Vegas, Nevada, United States
    • Cultured Foods Sp. z.o.o. Subsidiary · Poland
    • Elevated Softgels LLC Subsidiary · Delaware, United States
    • Star Sky Foods, LLC Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CV Sciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.9M6 Dec 31, 2025$1.8M6 Dec 31, 2024+6.3%
Accumulated depreciation$1.5M6 Dec 31, 2025$1.4M6 Dec 31, 2024+12.5%
Property and equipment, net$344.0K6 Dec 31, 2025$399.0K6 Dec 31, 2024−13.8%
Operating-lease assets (leased space)$347.0K6 Dec 31, 2025$94.0K6 Dec 31, 2024+269.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.0M6 Dec 31, 2025$971.0K6 Dec 31, 2024+4.5%
Intangible assets, net (excluding goodwill)$76.0K6 Dec 31, 2025$93.0K6 Dec 31, 2024−18.3%
Finite-lived intangibles, gross$116.0K6 Dec 31, 2025$116.0K6 Dec 31, 20240%
Accumulated amortization$46.0K6 Dec 31, 2025$22.0K6 Dec 31, 2024+109.1%
Finite-lived intangibles, net$76.0K6 Dec 31, 2025$93.0K6 Dec 31, 2024−18.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$4.1M6 Dec 31, 2025$4.9M6 Dec 31, 2024−16.5%
Raw materials$2.6M6 Dec 31, 2025$2.6M6 Dec 31, 2024+0.7%
Work in process$387.0K6 Dec 31, 2025$649.0K6 Dec 31, 2024−40.4%
Finished goods$1.1M6 Dec 31, 2025$1.7M6 Dec 31, 2024−33.9%

Properties, in its own words

As of December 31, 2025, our primary facility consists of approximately 6,000 square feet of leased office and warehouse space located in San Diego, California. The lease term is one year through May 31, 2026, with a one year renewal period. The total lease obligation over the estimated lease term of two years is approximately $0.3 million. The lease commenced on June 1, 2025.

In February 2025, we entered into a new lease agreement for our existing Elevated Softgels manufacturing facility. The facility is approximately 7,200 square feet and located in Grand Junction, Colorado. The lease term is for one year, with two one year renewal periods. The total lease obligation over the estimated lease term of two years is approximately $0.2 million. The lease commenced on April 1, 2025.

The rest of Item 2

We entered into a lease agreement for our manufacturing facility in Poland. The facility is approximately 2,400 square feet and located outside of Warsaw, Poland. The lease term is for two years and expires on September 30, 2026. Based on the present value of the lease payments, we recognized an operating lease asset and liability for operating leases of $0.1 million on October 1, 2024.

We believe that our existing facilities are sufficient to accommodate our current business operations.

Item 2 of the 10-K filed Mar 26, 2026.5

Leadership

Who has led CV Sciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Joseph Mona Jr.2014–2018
  2. Joseph D. Dowling2019–2025

President

  1. Michael Joseph Mona Jr.2014–2018

Chief financial officer

  1. Joseph D. Dowling2014–2018
  2. Joerg Grasser2019–2025
201520202025
Board members and other officers (13)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Cultured Foods Sp. z.o.o. Poland4
  • Elevated Softgels LLC Delaware4
  • Star Sky Foods, LLC Delaware4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • CannaVEST Corp.Feb 12, 2013 to Jan 4, 20163
  • Foreclosure Solutions, Inc.Jan 31, 2011 to Nov 30, 20123

Timeline

  1. Aug 13, 20268-K Results of operations; Other events30
  2. Jun 4, 20268-K Executive or director change; Shareholder vote31
  3. May 14, 20268-K Results of operations; Regulation FD disclosure32
  4. Apr 10, 20268-K Entered a material agreement; New debt or obligation33
  5. Mar 26, 20268-K Results of operations; Regulation FD disclosure34
  6. Mar 10, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares35
  7. Nov 13, 20258-K Results of operations; Regulation FD disclosure36
  8. Oct 10, 20258-K Entered a material agreement37
  9. Sep 18, 20258-K Entered a material agreement38
  10. Aug 13, 20258-K Results of operations; Regulation FD disclosure39
  11. Jun 5, 20258-K Shareholder vote40
  12. May 14, 20258-K Results of operations; Regulation FD disclosure41
  13. Nov 12, 2019New chief executive Joseph D. Dowling becomes CEO14
  14. Dec 17, 2014New chief executive Michael Joseph Mona Jr. becomes CEO15
  15. Jul 26, 2013Founded CV Sciences, Inc. is founded2

Calendar

Coming up

  1. Around Nov 12, 2026Next results, estimated About a quarter after its last report. The company hasn't announced the date.

When it reported results

  1. Aug 13, 2026Reported quarterly or annual results30
  2. May 14, 2026Reported quarterly or annual results32
  3. Mar 26, 2026Reported quarterly or annual results34
  4. Nov 13, 2025Reported quarterly or annual results36
  5. Aug 13, 2025Reported quarterly or annual results39
  6. May 14, 2025Reported quarterly or annual results41
  7. Mar 27, 2025Reported quarterly or annual results42
  8. Nov 14, 2024Reported quarterly or annual results43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

101 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 51 major events, 18 insider forms, 1 large holders, 11 other. The latest 20:

  1. Sep 9, 20264 PRIMARY DOCUMENT EDGAR
  2. Sep 9, 20263 PRIMARY DOCUMENT EDGAR
  3. Sep 9, 2026SCHEDULE 13G EDGAR
  4. Aug 13, 202610-Q EDGAR
  5. Aug 13, 20268-K EDGAR
  6. Jun 4, 20268-K EDGAR
  7. May 15, 202610-Q EDGAR
  8. May 14, 20268-K EDGAR
  9. Apr 15, 2026DEF 14A EDGAR
  10. Apr 10, 20268-K EDGAR
  11. Mar 26, 202610-K EDGAR
  12. Mar 26, 20268-K EDGAR
  13. Mar 10, 20268-K EDGAR
  14. Nov 13, 202510-Q EDGAR
  15. Nov 13, 20258-K EDGAR
  16. Oct 10, 20258-K EDGAR
  17. Sep 18, 20258-K EDGAR
  18. Aug 13, 202510-Q EDGAR
  19. Aug 13, 20258-K EDGAR
  20. Jun 5, 20258-K EDGAR

The 101 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 10 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 7, 2026CHEEVER CHARLIE E III10% ownerBuy94,854$0.02$1.9KForm 4
Aug 4, 2026CHEEVER CHARLIE E III10% ownerBuy108,000$0.02$2.2KForm 4
Jul 31, 2026CHEEVER CHARLIE E III10% ownerBuy1,730,000$0.02$34.6KForm 4
Jul 29, 2026CHEEVER CHARLIE E III10% ownerBuy60,000$0.02$1.2KForm 4
Jul 28, 2026CHEEVER CHARLIE E III10% ownerBuy1,830,000$0.02$36.6KForm 4
Jul 24, 2026CHEEVER CHARLIE E III10% ownerBuy470,075$0.02$9.4KForm 4
Jul 22, 2026CHEEVER CHARLIE E III10% ownerBuy272,500$0.02$5.5KForm 4
Jul 21, 2026CHEEVER CHARLIE E III10% ownerBuy335,000$0.02$6.7KForm 4
Jul 17, 2026CHEEVER CHARLIE E III10% ownerBuy749,000$0.02$15.0KForm 4
Jul 16, 2026CHEEVER CHARLIE E III10% ownerBuy91,387$0.02$1.8KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Charlie E. Cheever Iii.SCHEDULE 13G, 1 filing Sep 9, 202644

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Joseph Dowling68$294.0K$419.0K45
2025Joerg Grasser51$226.6K$308.0K45
2024Chief Executive Officer$294.6K$457.7K45
2024Chief Financial Officer$227.3K$343.3K45

SEC filer profile

How CV Sciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCV Sciences, Inc.1
  • CIK0001510964
  • Employer ID (EIN)80-09449705
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address9530 Padgett Street, Suite 107, San Diego, CA 921261
  • Phone866-290-21571
  • Shares outstanding225,829,128 as of Aug 11, 202613
  • Public float$7.0M as of Jun 30, 20255
  • AuditorHASKELL & WHITE LLP, Irvine, California PCAOB ID 200; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceJan 31, 20111
  • Filings430 in all: 8-K (152), 4 (84), 10-Q (46), 3 (20), DEF 14A (16), 10-K (15), SC 13D/A (12), D (7)1
    All 35 form types

    PRE 14A (7), S-1/A (7), 10-Q/A (6), SC 13G (6), 8-K/A (5), DEFA14A (5), NT 10-K (5), UPLOAD (5), 4/A (4), 424B5 (4), SC 13D (4), CORRESP (2), EFFECT (2), S-1 (2), SC 13G/A (2), 305B2 (1), 5 (1), 8-A12G (1), AW (1), CT ORDER (1), DEL AM (1), NT 10-Q (1), NTN 10Q (1), RW (1), S-3 (1), S-8 (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 26, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Apr 15, 2026
    Latest 8-K (8-K) Aug 13, 2026

Risk factors and legal proceedings

Legal proceedings

For a description of our material pending legal proceedings, please see Note 13, Commitments and Contingencies, to our consolidated financial statements included in Part IV in this Annual Report.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45